Corporate Presentation 2Q 2015
Sa fe Ha rbor Sta te me nt Special Note Regarding Forward ‐ Looking Statements This presentation contains forward ‐ looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward ‐ looking statements, including without limitation statements with respect to expectations regarding the timing of discussions with the FDA and/or USDA and approval and licensure of products; development programs, clinical trials and studies, including without limitation the timing of full enrollment in and the announcement of results of such trials and studies; commercialization and manufacturing of products, including without limitation establishing larger manufacturing capacities for AT ‐ 004 and AT ‐ 005; the sufficiency of financial resources; expected future cash balance and liquidity; licensing initiatives and collaborations; the Company’s plans and opportunities, including without limitation offering a unique portfolio of innovative therapeutics; and the Company’s belief that its products and product candidates will result in improved outcomes for pets. These forward ‐ looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward ‐ looking statements, including, but not limited to, the following: our limited operating history and expectations of losses for the foreseeable future; our lack of commercial sales; our failure to obtain any necessary additional financing; market conditions and our ability to raise capital under the shelf registration statement from the sale of our securities; our substantial dependence on the success of certain of our lead product candidates; our dependence on novel technologies and compliance with complex regulatory requirements; our inability to obtain regulatory approval for our existing or future product candidates; the lack of commercial success of our current or future product candidates; our inability to realize all of the anticipated benefits of our acquisitions of Vet Therapeutics and Okapi Sciences; uncertainties regarding the outcomes of studies regarding our products; the uncertainty of outcomes of the development of pet therapeutics, which is a lengthy and expensive process; effects of competition; our inability to identify, license, develop and commercialize additional product candidates; our failure to attract and keep senior management and key scientific personnel; our reliance on third ‐ party manufacturers, suppliers, partners and other third parties which conduct our target animal studies and certain other development efforts; unanticipated difficulties or challenges in the relatively new field of biologics development and manufacturing; our ability to market our products only for the treatment of indications for which they are approved; our small commercial organization; difficulties managing the growth of our organization; our significant costs of operating as a public company; risks related to the restatement of our financial statements for the year ended December 31, 2013 and the identification of a material weakness in our internal control over financial reporting; changes in distribution channels for pet therapeutics; consolidation of our customers; limitations on our ability to use our net operating carryforwards; impact of generic products; unanticipated safety or efficacy concerns; our limited patents and patent rights; our failure to comply with our intellectual property license obligations; our infringement of third party patents and challenges to our patents or rights; litigation resulting from the misuse of our confidential information; the uncertainty of the regulatory approval process; our failure to comply with regulatory requirements or obtain foreign regulatory approvals; our failure to report adverse medical events related to our products; legislative or regulatory changes; the volatility of our stock price; our status as an “emerging growth company,” as defined in the JOBS Act; the potential for dilution if we sell shares of our common stock in future financings; the significant control over our business by our principal stockholders and management; the potential that a significant portion of our total outstanding shares could be sold into the market in the near future; effects of anti ‐ takeover provisions in our charter documents and under Delaware law; and our intention not to pay dividends. These and other important factors discussed under the caption "Risk Factors" in the Company’s Annual Report on Form 10 ‐ K filed with the Securities and Exchange Commission, or SEC, on March 16, 2015, along with our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward ‐ looking statements made in this presentation. Any such forward ‐ looking statements represent management's estimates as of the date of this presentation. While we may elect to update such forward ‐ looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward ‐ looking statements should not be relied upon as representing our views as of any date subsequent to the date of this presentation. 2
Inve stme nt Hig hlig hts Large, growing market Portfolio approach De ‐ risked drug development Scalable and capital ‐ efficient Private ‐ pay First mover, pure ‐ play 3
De fining Pe t T he ra pe utic s Completed IPO Over 18 products Regain Rights to 3 products in in development AT ‐ 004 development 2010 2013 2014 2015 2016 Portfolio Expansion: Founded Introduction of Option Deals Lymphoma MAb Vet Therapeutics Okapi Sciences Advaxis Vet ‐ Stem Atopix 4
Our Ma rke t U.S. Pet Owners Spend ($Billions) Large and growing – 2014 U.S. pet spend of $58B Insensitive to recent recessions 68% of U.S. households – 96M cats – 83M dogs Medicalization drives growth – Historically, limited innovation – Pet therapeutics underrepresented Source: APPA. 5
T he E volution of Pe t Owne rship “Snoopy Generation” “Brian Generation” Pets are family whose medical needs merit quality care 6
A F a vora ble Compa rison Humans Humans Pets Pets Development Development Multiple Species Steps Direct to Species ~$1.3B ~$10M ~10 Years ~5 Years Third Party Payer Private Pay Commercial Commercial Generic Pressure Innovator Brand Loyalty Difficult & Indirect Accessible & Direct 7
Building the Portfolio Key Attributes Early De ‐ Risking Unmet medical need Toxicology data are available High incidence or prevalence Manufacturing is scaled ‐ up Known mechanism of action Effectiveness data are available Nuance in science “Early de ‐ risking” Leveraging the investment in human therapeutics Pharmaceuticals Biologics US and OUS 8
F DA a nd USDA T ime line s Year 1 Year 2 Year 3 Year 4 Year 5 FDA Center for Veterinary Medicine Proof of Concept INAD Chemistry, Mfg. & Controls (CMC) Safety Pilot ‐‐‐ > Pivotal Effectiveness Labeling, FOI Summary, Other Administrative NADA Year 1 Year 2 Year 3 Year 4 Year 5 USDA ‐ Center for Veterinary Biologics Proof of Concept Manufacturing File for Product License Preclinical Field Safety and Efficacy Conditional Product License* Extended Field Safety and Efficacy Study Full Product License * Conditional licenses granted under special circumstances 9
Our Pipe line Proof of Pivotal/ Pilot Concept Commercial AT ‐ 004 AT ‐ 001 AT ‐ 006 AT ‐ 010 AT ‐ 009 Anti ‐ CD20 (grapiprant) Monoclonal Antibody Feline Herpesvirus Atopic Dermatitis Mast Cell Tumor Degenerative Joint Disease B ‐ cell Lymphoma AT ‐ 005 AT ‐ 002 AT ‐ 012 AT ‐ 011 AT ‐ 007 Anti ‐ CD52 (capromorelin) Monoclonal Antibody Feline Calicivirus Canine Parvovirus Feline Immunodeficiency Virus Weight Gain T ‐ cell Lymphoma AT ‐ 003 AT ‐ 001 AT ‐ 017 AT ‐ 015 AT ‐ 018 (bupivacaine liposome (grapiprant) injectable suspension) Lymphoma Lymphoma Atopic Dermatitis Osteoarthritis Post ‐ operative Pain AT ‐ 002 AT ‐ 002 AT ‐ Beta AT ‐ Iota AT ‐ 016 (capromorelin) (capromorelin) Epilepsy Periodontal Allogeneic Stem Cell OA Weight Gain Appetite Stimulant AT ‐ 003 AT ‐ 008 (bupivacaine liposome injectable suspension) Lymphoma Post ‐ operative Pain AT ‐ 014 Osteosarcoma 10
Our Industry Products at Field Study Stage in Dogs and Cats ~15 ~3 ~2 Non ‐ confidential materials ~1 ~1 (may not be comprehensive) Historic Productivity of the Animal Health Industry Total number of NADAs NADAs for dogs / cats Pet therapeutic NCEs* 2011 12 6 2 2012 11 6 0 2013 6 4 2 2014 11 4 0 * NCE defined as new chemical entity not previously approved in humans or animals (excluding parasite drugs). 11
Industry Re c og nition 12
Recommend
More recommend
